The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: ReNeuron appoints administrators as rescue talks fail

Wed, 20th Mar 2024 18:11

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Transense Technologies PLC - Bicester, Oxfordshire-based developer of specialist sensor systems for vehicles - Appoints Ryan Maughan as managing director with immediate effect. Maughan joined Transense on a part-time basis as business development director of SAWsense on December 1 2021.

----------

ReNeuron Group PLC - Brigdend, Wales-based stem cell and exosomes technology company - Appoints Cork Gully LLP as administrators. Says talks with creditors to establish the solvency of the business, have taken place, with a particular focus on finding solutions that would allow the group to continue trading on a lower cost model. However, to date, these discussions have not progressed sufficiently to establish the precise solvency status of the business. Therefore, due to this increased financial uncertainty the decision has been taken to appoint administrators. Stresses discussions with potential investors, partners and creditors will remain open throughout the administration process.

----------

Downing Strategic Micro-Cap IT PLC - London-based investment trust - Updates on return of capital to shareholders. Says that the level of cash within the company's portfolio against the net asset value as at March 6 has increased to over 40%. Therefore, anticipates that it will be able to undertake an issue and redemption of B shares on or around April 4. This will enable a return capital of around 26.0 pence per share to shareholders. Says this is significantly improved on the previous anticipated return of around GBP10 million, or 21.5p per share.

----------

BAE Systems PLC - London-based defence, aerospace and security company - Announces private placement of notes to institutional buyers. Notes to be issued consist of USD800 million in aggregate principal amount of 5.000% notes due 2027, USD1.25 billion in aggregate principal amount of 5.125% notes due 2029, USD500 million in aggregate principal amount of 5.250% notes due 2031, USD1.50 billion in aggregate principal amount of 5.300% notes due 2034 and USD750 million in aggregate principal amount of 5.500% notes due 2054. Net proceeds will be used to refinance USD4.0 billion in aggregate principal amount outstanding under the bridge loan facility agreement incurred to fund part of the acquisition price of Ball Aerospace, and for general corporate purposes. Notes the offering is expected to close on or about March 26.

----------

Cloudbreak Discovery PLC - Vancouver, Canada-based natural resource project generator - Says Andrew Male and Paul Gurney have joined the Board of G2 Energy Ltd. Male is interim chief executive of Cloudbreak. Gurney is a non-executive director. Male states: "Paul and I look forward to working with G2 and their team in order to develop and enhance the production assets that G2 hold. Our primary focus will be to assist G2 in generating more revenue and looking at additional acquisitions that are accretive to the Cloudbreak investment and G2's underlying business operations."

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
5 Jul 2018 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 6 July SVM UK Emerging FundFull Year Results Monday 9 July GroupHalf

Read more
19 Apr 2018 13:17

ReNeuron Wins GBP1.5 Million Grant For Stem Cell Therapy Development

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said it is the "lead" industry participant in a new GBP1.5 million grant from the UK's innovation agency Innovate grant has to

Read more
3 Apr 2018 13:29

Portugal looks to renewables as March output tops mainland power demand

LISBON, April 3 (Reuters) - For the first time in at least four decades, Portugal's monthly renewable energy production in March exceeded power demand

Read more
26 Mar 2018 15:53

ReNeuron Now Expects hRPC Stem Cell Trial Data In First Half Of 2019

LONDON (Alliance News) - ReNeuron Group PLC on Monday said it has decided to adjust the number of clinical sites for its CTX stem cell therapy candidate study, and now expects

Read more
5 Dec 2016 11:06

ReNeuron's first half revenues supported by new drug developments

(ShareCast News) - ReNeuron, an AIM-listed UK based developer of cell-based therapeutics, saw first half revenues double due to a series of successful drug trials. Revenues were £22,000 for the six months ended 30 September 2016 up from £11,000 in the first half of 2015. During the period, the grou

Read more
4 Dec 2016 14:45

Sunday share tips: ReNeuron, Clipper Logistics, RM Secured Direct Lending

(ShareCast News) - Shares of ReNeuron are for brave investors only, said the Sunday Times' Inside the City column. The stem cell pioneer is scheduled to publish the results of second-phase clinical trials of its potential stroke paralysis treatment alongside its interim results on Monday. ReNeuron's

Read more
6 Sep 2016 11:38

ReNeuron reports positive progress in clinical trials

(ShareCast News) - UK-based developer of cell-based therapeutics ReNeuron Group provided a trading update ahead of its annual general meeting on Tuesday. The AIM-traded firm reported that all patients have been treated in the PISCES II Phase II clinical trial of its CTX cell therapy candidate for pa

Read more
7 Jul 2016 09:37

ReNeuron Annual Loss Widens As Product Trials Ramp Up

Read more
4 Jul 2016 15:16

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
13 Jun 2016 07:58

ReNeuron Completes Phase II Stroke Therapy Trial Patient Recruitment

Read more
9 Jun 2016 08:55

ReNeuron Selects Glioblastoma Multiforme As First Clinical Target

Read more
8 Jun 2016 08:36

ReNeuron Progressing Blindness Candidate Through Phase I/II Trial

Read more
15 Mar 2016 09:52

ReNeuron Says First Patient Treated For Retinitis Pigmentosa

Read more
23 Feb 2016 16:05

ReNeuron moving to purpose-built labs in Wales

(ShareCast News) - ReNeuron's office, laboratory and manufacturing staff were preparing for a space upgrade this week, with the firm announcing it was moving from Guildford to Pencoed in South Wales. The AIM-traded stem cell therapy development company said the new location was purpose-built, and wo

Read more
23 Feb 2016 09:16

ReNeuron Relocating Headquarters To South Wales Business Park

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.